Briefing
MODERN: MRD-guided adjuvant nivolumab, with or without relatlimab, in urothelial cancer
Alliance A032103 randomizes patients after surgery for muscle-invasive urothelial cancer of the bladder, renal pelvis, ureter, or urethra according to ctDNA, escalating MRD-positive patients to nivolumab plus relatlimab versus nivolumab and comparing surveillance with nivolumab in MRD-negative patients.
- Design: Phase 2/3 · Recruiting